BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...

Feb 12 (Reuters) - BridgeBio Pharma said its experimental therapy boosted growth rates in children with a rare genetic ...

BridgeBio Pharma’s experimental drug for the most common cause of dwarfism accelerated children’s growth in a pivotal clinical trial.

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

The latest in a string of clinical wins, the late-stage data gives the company strong footing to compete with BioMarin's top seller.

BridgeBio Pharma Inc. BBIO stock is surging on Thursday and nearing the upper end of its 52-week range of $28.33-$84.94, ...

If infigratinib gains approval, the drug could challenge BioMarin’s predicted blockbuster, Voxzogo, on the achondroplasia market.

Cierra Moore's daughter Lakelynn was diagnosed at birth with rhizomelic chondrodysplasia punctata type 1, which is a rare and ...

Babies undergo a newborn screening test for inherited metabolic disorders within seven days of birth. The test checks for risk factors such as hypothyroidism, phenylketonuria and maple syrup urine ...

Feb 12 (Reuters) - BridgeBio Pharma said on Thursday its experimental therapy boosted growth rates in children with a rare ...